About
Turn Therapeutics files prospectus relates to offer, sale of up to 7 mln shares
Klotho Neurosciences plans to acquire assets from Turn Biotechnologies, focusing on technologies for tissue restoration and cellular rejuvenation. The deal, contingent on due diligence and a definitive agreement, includes Turn's Epigenetic Reprogramming of Age (ERA) platform and eTurna RNA delivery system. This acquisition may lead to a partnership worth up to $300 million with a South Korean pharmaceutical company. Klotho aims to rebrand post-acquisition and integrate key personnel from Turn, enhancing its mission in longevity therapeutics.
Klotho Neurosciences, Inc. has signed a Letter of Intent to acquire key assets from Turn Biotechnologies, including the ERA platform and eTurna RNA delivery system, aimed at regenerative therapies. The deal, involving cash and stock, also includes a $300 million partnership with a South Korean pharmaceutical company, emphasizing the commercial potential of Turn’s technologies. Klotho plans to rebrand and integrate Turn’s management and R&D teams post-transaction.
Mount Logan Capital Inc. and 180 Degree Capital Corp. have successfully closed their all-stock strategic business combination, creating a new entity expected to trade on NASDAQ under the symbol "MLCI" starting September 15, 2025. The merger, valued at approximately $122.7 million, will see Mount Logan shareholders owning 56.4% and 180 Degree Capital shareholders 43.6% of the combined company. The merger aims to enhance growth and access to U.S. capital markets, with plans for liquidity programs totaling up to $25 million over the next 24 months.
180 Degree Capital held a meeting on August 22, 2025, where shareholders voted in favor of resolutions enabling the company to proceed with the Business Combination.
